Omega 3 FA Supplements as Augmentation in the Treatment of Depression
To assess the efficacy of Omega 3 Fatty acid (Omega 3 FA) augmentation of desvenlafaxine (DVS) compared to placebo augmentation of DVS when used to treat depression and anxiety symptoms in patients with select medical conditions (cancer, cardiovascular diseases and diabetes).
Major Depression|Cancer|Diabetes|Cardiovascular Diseases
DRUG: Desvenlafaxine|DIETARY_SUPPLEMENT: Omega 3 Fatty acids|DRUG: Placebo (for Omega 3 fatty acid supplement)
Hospital Anxiety and Depression Scale, Hospital Anxiety and Depression Scale: This is a validated scale for measuring depression/anxiety symptoms in patients with medical conditions., 12 weeks from baseline
Montgomery-Asberg Depression Rating Scale (MADRS), 12 weeks from baseline|Short Form Health Survey (SF-12), 12 weeks from baseline|Visual Analog Scale for Energy (VAS-E), 12 weeks from baseline|Visual Analog Scale for Pain (VAS-P), 12 weeks from baseline|Leeds Sleep Evaluation Questionnaire (LSEQ), 12 weeks from baseline
To assess the efficacy of Omega 3 Fatty acid (Omega 3 FA) augmentation of desvenlafaxine (DVS) compared to placebo augmentation of DVS when used to treat depression and anxiety symptoms in patients with select medical conditions (cancer, cardiovascular diseases and diabetes).